SERB Pharmaceuticals has appointed Dr Vignesh Rajah as its new Chief Medical Officer, bringing over 20 years of global experience in medical and clinical leadership across US and European pharmaceutical and biotech sectors.
Vanessa Wolfeler, CEO of SERB, said: “Vignesh’s unique expertise as both a physician and an experienced CMO reinforces our unwavering commitment to advancing patient care and improving health outcomes. His deep clinical insight and passion for evidence-based innovation will help us realise the full potential of our therapies.”
Vignesh, who was most recently CMO at US biotech Y-mAbs Therapeutics Inc, has held senior medical roles at Sanofi, Wyeth and GSK. His therapeutic experience spans rare diseases, oncology, immunology, respiratory and vaccines. Before entering industry, he practised as a paediatric critical care specialist in leading London hospitals.
Vignesh said: “I’m thrilled to join SERB at such a pivotal moment in its growth. The company’s focus on rare disease and emergency medicines and its commitment to addressing urgent medical needs strongly align with my own values as a physician and medical leader. I look forward to working with our teams and our partners in the medical community to bring meaningful innovation to patients around the world.”
The appointment marks a key milestone in SERB’s strategy to expand its scientific and medical capabilities, support new product launches and deepen engagement with the global medical community.
